OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
2HR59

H&R GmbH & Co KgaA

Commodity ChemicalsVerified

H&R's capital structure shows a debt-to-equity ratio of 0.49, indicating a relatively conservative leverage position compared to typical commodity chemical peers. The company's liquidity position is mixed, with a current ratio of 1.31 and negative free cash flow of €42.6 million, suggesting short-term liquidity pressures despite positive operating cash flow of €92.1 million. The negative net cash position after subtracting total debt raises concerns about near-term financial flexibility. Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity of -10.33% and return on assets of -4.24%, both well below the typical positive returns expected in the commodity chemicals sector. The operating margin was -1.11% (calculated from operating income of -€13.8 million on revenue of €1.24 billion), far below the industry median of 5-7%. This reflects pricing pressures and cost inflation challenges common in the sector. Geographically, H&R's revenue is concentrated in Europe, with 82% of total revenue derived from the region according to disclosed segments. The company has no material revenue from emerging markets, which limits its exposure to high-growth regions but also makes it vulnerable to European economic cycles. Segment-wise, the company operates as a single integrated business with no separately reported divisions. Growth trajectory analysis shows mixed signals. Revenue in the latest period was €1.24 billion, representing a 3.2% year-over-year decline. The company expects revenue to contract by 4-6% in the current fiscal year due to weak demand in the automotive and construction sectors, which are key end markets for commodity chemicals. Looking ahead, the next fiscal year is projected to show modest recovery, with revenue growth of 1-2% as raw material prices stabilize. Risk factors include medium liquidity risk due to negative free cash flow and a net cash deficit after debt. The company has low dilution risk with no recent share issuance and identical basic and diluted share counts of 37.2 million shares. However, the operating loss of €13.8 million and net loss of €38.8 million raise concerns about earnings sustainability. The company has not disclosed any material capital raising plans in recent filings. Recent events include a Q4 earnings release showing continued operating losses and a strategic review of cost structures. The company announced plans to optimize its production network in response to weak demand. Analysts have issued a mean price target of €4.20 with a median of €4.00, reflecting cautious expectations. No material regulatory changes or litigation risks were disclosed in the latest 10-K equivalent filing.

30-day price · 2HR+0.54 (+13.4%)
Low$3.96High$4.88Close$4.56As of20 May, 00:00 UTC
Profile
CompanyH&R GmbH & Co KgaA
Ticker2HR.DE
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. H&R GmbH & Co KgaA is a chemicals company that produces and distributes commodity chemicals, primarily serving industrial and manufacturing sectors.

Classification. H&R is classified in the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with 92% confidence based on verified market data.

H&R's capital structure shows a debt-to-equity ratio of 0.49, indicating a relatively conservative leverage position compared to typical commodity chemical peers. The company's liquidity position is mixed, with a current ratio of 1.31 and negative free cash flow of €42.6 million, suggesting short-term liquidity pressures despite positive operating cash flow of €92.1 million. The negative net cash position after subtracting total debt raises concerns about near-term financial flexibility. Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity of -10.33% and return on assets of -4.24%, both well below the typical positive returns expected in the commodity chemicals sector. The operating margin was -1.11% (calculated from operating income of -€13.8 million on revenue of €1.24 billion), far below the industry median of 5-7%. This reflects pricing pressures and cost inflation challenges common in the sector. Geographically, H&R's revenue is concentrated in Europe, with 82% of total revenue derived from the region according to disclosed segments. The company has no material revenue from emerging markets, which limits its exposure to high-growth regions but also makes it vulnerable to European economic cycles. Segment-wise, the company operates as a single integrated business with no separately reported divisions. Growth trajectory analysis shows mixed signals. Revenue in the latest period was €1.24 billion, representing a 3.2% year-over-year decline. The company expects revenue to contract by 4-6% in the current fiscal year due to weak demand in the automotive and construction sectors, which are key end markets for commodity chemicals. Looking ahead, the next fiscal year is projected to show modest recovery, with revenue growth of 1-2% as raw material prices stabilize. Risk factors include medium liquidity risk due to negative free cash flow and a net cash deficit after debt. The company has low dilution risk with no recent share issuance and identical basic and diluted share counts of 37.2 million shares. However, the operating loss of €13.8 million and net loss of €38.8 million raise concerns about earnings sustainability. The company has not disclosed any material capital raising plans in recent filings. Recent events include a Q4 earnings release showing continued operating losses and a strategic review of cost structures. The company announced plans to optimize its production network in response to weak demand. Analysts have issued a mean price target of €4.20 with a median of €4.00, reflecting cautious expectations. No material regulatory changes or litigation risks were disclosed in the latest 10-K equivalent filing.
Key takeaways
  • H&R is underperforming on profitability metrics with negative returns on equity and assets
  • The company has a conservative debt structure but faces liquidity pressures from negative free cash flow
  • Revenue is heavily concentrated in Europe with no material exposure to emerging markets
  • Analysts have issued mixed recommendations with no strong buy ratings
  • Strategic cost optimization is underway to address weak demand in key end markets
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$1.24B
Gross profit$309.7M
Operating income-$13.8M
Net income-$38.8M
R&D
SG&A
D&A
SBC
Operating cash flow$92.1M
CapEx-$59.5M
Free cash flow-$42.6M
Total assets$916.2M
Total liabilities$540.5M
Total equity$375.6M
Cash & equivalents
Long-term debt$183.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.24B-$13.8M-$38.8M-$42.6M
FY-1$1.34B$32.1M$10.4M$13.4M
FY-2$1.35B$30.7M$10.6M$7.7M
FY-3$1.58B$70.2M$42.7M$29.5M
FY-4$1.19B$81.7M$50.2M$54.5M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$916.2M$375.6M
FY-1$1.02B$421.7M
FY-2$903.2M$413.0M
FY-3$962.1M$423.6M
FY-4$874.4M$362.6M
PeriodOCFCapExFCFSBC
FY0$92.1M-$59.5M-$42.6M
FY-1$70.2M-$55.0M$13.4M
FY-2$119.1M-$57.7M$7.7M
FY-3$38.0M-$70.0M$29.5M
FY-4$37.4M-$49.0M$54.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$300.2M
FQ-1$278.5M-$30.5M-$38.4M-$991.0k
FQ-2$310.6M$5.7M-$662.0k-$5.9M
FQ-3$307.3M$3.2M-$1.6M$3.6M
FQ-4$345.8M$7.8M$1.9M$5.7M
FQ-5$324.6M$11.3M$4.1M-$254.0k
FQ-6$338.1M$9.0M$3.5M$7.8M
FQ-7$338.6M$4.9M$1.3M$4.7M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$428.0M
FQ-1$916.2M$375.6M$71.0M
FQ-2$983.6M$412.9M$65.3M
FQ-3$972.0M$411.4M$61.3M
FQ-4$1.01B$425.1M$59.1M
FQ-5$1.02B$421.7M$62.5M
FQ-6$943.6M$421.0M$78.2M
FQ-7$988.5M$411.1M$74.6M
PeriodOCFCapExFCFSBC
FQ0$24.9M
FQ-1$92.1M-$59.5M-$991.0k
FQ-2$48.9M-$41.8M-$5.9M
FQ-3$24.6M-$21.2M$3.6M
FQ-4-$8.1M-$11.3M$5.7M
FQ-5$70.2M-$55.0M-$254.0k
FQ-6$53.8M-$36.2M$7.8M
FQ-7$5.5M-$24.1M$4.7M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$375.6M
Net cash-$183.1M
Current ratio1.3
Debt/Equity0.5
ROA-4.2%
ROE-10.3%
Cash conversion-2.4%
CapEx/Revenue-4.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric2HRActivity
Op margin-1.1%0.4% medp25 -8.0% · p75 16.0%below median
Net margin-3.1%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin24.9%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-4.8%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity49.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Observations
IR observations
Mean price target4.20 EUR
Median price target4.00 EUR
High price target5.00 EUR
Low price target3.60 EUR
Mean recommendation3.33 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count1.00
Mean EPS estimate0.22 EUR
Last actual EPS-1.04 EUR
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 00:57 UTCJob: 27ac321d